Category Company News

Gilead Sciences acquires CymaBay Therapeutics

Gilead Sciences and CymaBay Therapeutics announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for…

Synthekine announced a worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.

Synthekine Inc., an engineered cytokine therapeutics company, today announced a worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. The collaboration will focus on advancing Synthekine’s multiple approaches to optimizing IL-10, with…